CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been given a consensus recommendation of “Hold” by the twelve research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $32.67.
A number of equities research analysts have recently issued reports on CTMX shares. Wedbush started coverage on CytomX Therapeutics in a research report on Thursday, September 7th. They set an “outperform” rating and a $26.00 target price on the stock. Nomura boosted their target price on CytomX Therapeutics to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th. ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Bank of America Corporation boosted their target price on CytomX Therapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th. Finally, Jefferies Group LLC set a $25.00 target price on CytomX Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 25th.
In other news, insider William Michael Kavanaugh sold 48,368 shares of CytomX Therapeutics stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $24.34, for a total transaction of $1,177,277.12. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $15.00, for a total value of $37,500.00. Following the transaction, the chief financial officer now owns 19,626 shares in the company, valued at approximately $294,390. The disclosure for this sale can be found here. Insiders have sold 177,794 shares of company stock worth $3,806,089 in the last quarter. 4.70% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the company. Citadel Advisors LLC purchased a new position in shares of CytomX Therapeutics during the first quarter valued at $313,000. Goldman Sachs Group Inc. purchased a new position in CytomX Therapeutics in the first quarter valued at about $190,000. KCG Holdings Inc. purchased a new position in CytomX Therapeutics in the first quarter valued at about $388,000. American Century Companies Inc. purchased a new position in CytomX Therapeutics in the second quarter valued at about $922,000. Finally, Sphera Funds Management LTD. grew its stake in CytomX Therapeutics by 33.3% in the second quarter. Sphera Funds Management LTD. now owns 200,000 shares of the biotechnology company’s stock valued at $3,100,000 after purchasing an additional 50,000 shares in the last quarter. Institutional investors and hedge funds own 59.97% of the company’s stock.
CytomX Therapeutics (NASDAQ:CTMX) traded up 0.40% during mid-day trading on Thursday, hitting $20.09. The company had a trading volume of 261,495 shares. The company’s 50 day moving average price is $18.80 and its 200-day moving average price is $15.90. CytomX Therapeutics has a one year low of $9.85 and a one year high of $24.67. The company’s market cap is $740.66 million.
CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.30). The company had revenue of $8.75 million for the quarter, compared to analyst estimates of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. Equities research analysts anticipate that CytomX Therapeutics will post ($1.47) EPS for the current fiscal year.
WARNING: This news story was posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://weekherald.com/2017/10/19/cytomx-therapeutics-inc-ctmx-receives-consensus-rating-of-hold-from-analysts.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.